The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
about
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsCardiovascular pharmacogenomics: current status and future directionsMATE2 Expression Is Associated with Cancer Cell Response to MetforminPharmacogenomics in type 2 diabetes: oral antidiabetic drugs.Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK).Metformin pharmacogenomics: current status and future directions.Metformin pharmacogenomics: biomarkers to mechanisms.An update on the pharmacogenomics of metformin: progress, problems and potential.Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene.Verapamil decreases the glucose-lowering effect of metformin in healthy volunteersTargeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metforminPharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.What do drug transporters really do?The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy VolunteersMetformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.Pharmacogenetics of oral antidiabetic drugs.Different effect of testosterone and oestrogen on urinary excretion of metformin via regulating OCTs and MATEs expression in the kidney of mice.Metformin represses drug-induced expression of CYP2B6 by modulating the constitutive androstane receptor signaling.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?Genetics of drug response in type 2 diabetes.Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes.Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity.Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).Renal Drug Transporters and Drug Interactions.A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.Limited sampling strategy for determining metformin area under the plasma concentration-time curve.Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.Genetic polymorphisms of multidrug and toxin extrusion proteins (MATE1 and MATE2) in South Indian populationIndinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1).
P2860
Q26751138-D344DA7B-ED5B-42BC-8024-ABBF0786FCE7Q26801183-76445B3D-E31C-4E96-BB1C-E0AB9C8381C7Q28555000-0F1CFCF3-55C0-4C68-A03B-ED36044A18B2Q30248914-BBFA33B3-B298-4A22-A87E-4BEE3FCB3E23Q33658321-C1744AB9-9858-4375-9885-4571809441CAQ33946957-15E72A9E-BE26-4530-85ED-47C3A081DBAAQ33959731-A5DBB41A-07D2-4E68-A6E7-31ACD4A526BFQ33959783-C53F09AD-DA01-46D3-BC37-2DAACDE92416Q34003050-85557FD5-0978-4CB0-A594-283F9CDF63D0Q34224429-F05ED715-EFA3-4AE4-B6B7-63508358FAA5Q34438700-05CF302F-C77E-4A75-9569-483F67030DB5Q34635590-F5B21D77-301F-48AB-8D75-C120ED47FF73Q35745939-1C2DFBDC-10AE-4F12-BC90-5027C82E63E4Q36412220-DAAA9FF4-E546-4A14-B24E-633E1C67E13CQ36571217-B358EEA6-C502-49BD-A6A9-36EED4466E95Q36689589-7A12FDBD-4882-4E27-A5B6-7F3354368920Q36709745-5969FDFB-DE4E-4D92-B321-0B59EC5F888AQ36924379-61A66BB7-4317-443F-94AD-DB8459936652Q36999783-1FBBAB85-E148-4B56-97FA-B17F97C10893Q37222650-0E007FD6-EE90-4BC4-8C60-92E33E3AD9B8Q37353476-9D00C62E-2687-45EC-88FC-65C8BB688282Q37466761-DD6C6648-6DAD-4407-ADA3-74E12B469AA3Q37553490-393A4C5B-9849-4E41-9D16-2D90F77857A3Q38086611-61E47DD6-0098-4D0C-B10F-D4D789A7F784Q38110432-F242F3C4-E24D-40A9-B24E-C18EFBB6105DQ38270699-8F8F7969-C20F-41A4-B8F5-06944DBD2FFBQ38480670-BB7D5380-EA1A-4AE4-B4DA-C2091D5CD66CQ38607553-287004A9-B1F6-4966-A27D-40BC744B98BAQ38647822-814C078D-3B03-440A-B924-C5D8A9C0209DQ38811683-5874C707-BB47-4F76-9F87-014BEEDAE799Q38816602-623C5318-B88A-4EC7-A6F0-17DA39103BF8Q38831370-C8FD19F0-0C45-4C4C-9DE6-223CAC2C6B94Q38888365-4F560A37-D8AB-471A-ACEF-09488CA54079Q39031270-5B5234B9-B8C9-4063-BAC2-0B8484B2E552Q39140289-AC08F511-ACC1-4383-B760-249BA0E15623Q39602527-623794F1-322C-49B8-9E0B-A82746C99648Q39669192-5D02016B-561D-4432-BDBC-E1F75C227553Q40827759-201458B6-E675-453F-A691-62E4F3FFBDFAQ42106306-BBCEC499-FBFB-4F10-B3E2-4A2807E37789Q47230742-2050638C-2A13-462B-BD39-787484289B2F
P2860
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The effect of novel promoter v ...... pharmacodynamics of metformin.
@en
type
label
The effect of novel promoter v ...... pharmacodynamics of metformin.
@en
prefLabel
The effect of novel promoter v ...... pharmacodynamics of metformin.
@en
P2093
P2860
P356
P1476
The effect of novel promoter v ...... pharmacodynamics of metformin
@en
P2093
A H Ramirez
K M Giacomini
K M Morrissey
R A Castro
P2860
P304
P356
10.1038/CLPT.2012.210
P407
P577
2012-10-17T00:00:00Z